Chinese experts consensus of treat-and-extend regimen for management of neovascular age-related macular degeneration by intravitreal injection of aflibercept (2021)

Author: Treat-and-Extend Regimen for Management of Neovascular Age-related Macular Degeneration Chinese Experts Consensus Group
DOI: 10.3760/cma.j.cn115989-20210311-00162
Published 2021-07-10
Cite asChin J Exp Ophthalmol, 2021, 39(7): 577-584.

Abstract

Neovascular age-related macular degeneration (nAMD) is one of the leading causes of visual impairment and blindness.Using treat-and-extend (T&E) regimen, aflibercept has been proven effective in nAMD treatment.Decreased intravenous injections and follow-up visits greatly reduce financial and follow-up burdens on nAMD patients as well as doctors.However, ophthalmologists in China still lack systematic understanding of the advantages, standardized treating pathway, clinical practice and patients’ gains of aflibercept T&E regimen, which greatly limits the extensive promotion and rational use in nAMD treatment.At the beginning of 2020, experts in relevant research fields summarized clinical problems existing in nAMD treatment with aflibercept T&E regimen in China.Based on an extensive survey of the latest progress of nAMD treatment, pathogenesis, drug mechanism, previous relevant research results and guidelines/consensus at home and abroad, and in combination with clinical practice and national conditions in relevant fields in China, a consensus was discussed and formulated.This publication would provide a recommendation for nAMD treatment with aflibercept T&E regimen, which would be helpful for clinicians in China to better understand and standardize the application of aflibercept T&E regimen in nAMD treatment.

Key words:

Age-related macular degeneration; Vascular endothelial growth factor; Choroidal neovascularization; Treat-and-extend regimen; Experts consensus; Aflibercept

Contributor Information

Treat-and-Extend Regimen for Management of Neovascular Age-related Macular Degeneration Chinese Experts Consensus Group
(Read 29 times, 1 visits today)
Updated: July 27, 2021 — 1:27 am